AI-designed enhancers control gene expression in healthy mammalian cells
CRG researchers measured more than 64,000 synthetic enhancers across seven stages of blood-cell development and found that enhancer combinations can activate genes in one cell type but repress them in another. The AI model used those measurements to design previously unseen regulatory DNA sequences that drove the intended cell-selective reporter expression in mouse blood cells.
Technology: Machine-learning enhancer design model developed by Lars Velten's group
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: CRG researchers measured more than 64,000 synthetic enhancers across seven stages of blood-cell development and found that enhancer combinations can activate genes in one cell type but repress them in another.
- Still unknown: The enhancer designs are proof-of-concept reporter regulators, tested in mouse blood cells; this is not evidence of a safe or effective gene therapy. The paper's Cell page redirected to a cookie wall, so detailed findings rely on the CRG's linked official summary.
- AI role: Researchers used large-scale enhancer activity measurements in healthy blood-cell models to train the model, which generated synthetic DNA enhancers for specified cell-type expression patterns; experiments tested the designs in mouse blood cells.
Evidence sources: https://www.crg.eu/en/news/ai-designed-dna-controls-genes-healthy-mammalian-cells-first-time
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 37 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.